THERAPEUTICS and DIAGNOSTICS for PROTEIN MISFOLDING DISEASES
WHAT WE DO
Discover effective drugs that can be safely used in the early stages Alzheimer’s disease (AD) and other major neurodegenerative disorders, thus improving the quality of life and longevity of people with such diseases and, to develop diagnostics for early detection and treatment monitoring of Alzheimer’s disease (AD) and other major neurological disorders.
TREVENTIS technology is founded in our proprietary, patent-pending computer model of aggregation, the "common conformational motif" or CCM. We have used this pioneering model of aggregation to virtually screen, identify, and optimize several classes of potent, drug-like compounds that inhibit the aggregation of a wide variety of amyloid proteins.
WHO WE ARE
TREVENTIS™ Corporation is an early stage biotechnology company focused on diseases associated with protein misfolding such as Alzheimer’s, Parkinson’s and Huntington’s. read more
Treventis is currently seeking a postdoctoral fellow in biology.